Free Trial
CVE:BCT

BriaCell Therapeutics (BCT) Stock Price, News & Analysis

BriaCell Therapeutics logo
C$10.60 -0.42 (-3.81%)
As of 12/30/2021

About BriaCell Therapeutics Stock (CVE:BCT)

Key Stats

Today's Range
C$10.60
C$11.07
50-Day Range
C$10.60
C$10.60
52-Week Range
C$3.50
C$15.75
Volume
3,402 shs
Average Volume
12,671 shs
Market Capitalization
C$168.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$15.00
Consensus Rating
N/A

Company Overview

Receive BCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCT Stock News Headlines

BriaCell Therapeutics Slide After Equity Offer
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.tc pixel
See More Headlines

BCT Stock Analysis - Frequently Asked Questions

BriaCell Therapeutics' stock was trading at C$10.60 at the start of the year. Since then, BCT stock has increased by 0.0% and is now trading at C$10.60.

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), BMO MSCI India ESG Leaders Index ETF (ZID), Athersys (ATHX), Anavex Life Sciences (AVXL), Cardium Therapeutics (CRXM) and Inovio Pharmaceuticals (INO).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:BCT
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
C$15.00
Low Price Target
C$15.00
Potential Upside/Downside
+41.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
129.63
Quick Ratio
128.68

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$3.34 per share
Price / Cash Flow
3.17
Book Value
C$3.60 per share
Price / Book
2.94

Miscellaneous

Outstanding Shares
15,913,000
Free Float
N/A
Market Cap
C$168.68 million
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (CVE:BCT) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners